Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00006504

Trial Description

start of 1:1-Block title

Title

Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

FIRSTANA

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Primary Objective:

- To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m² (Arm A) or 20
mg/m² (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS)
in patients with metastatic castration resistant prostate cancer (mCRPC) and not
previously treated with chemotherapy.

Secondary Objectives:

- To evaluate safety in the 3 treatment arms.

- To compare efficacy of cabazitaxel at 20 mg/m² and 25 mg/m² to docetaxel for:

- Progression Free Survival (PFS) (RECIST 1.1)

- Tumor progression free survival (RECIST 1.1)

- Tumor response in patients with measurable disease (RECIST 1.1),

- PSA response

- PSA-Progression free survival (PSA-PFS).

- Pain response in patients with stable pain at baseline

- Pain progression free survival

- Time to occurrence of any skeletal related events (SRE)

- To compare Health-Related Quality of Life (HRQL).

- To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Patients will be treated until progressive disease, unacceptable toxicity, or patient's
refusal of further study treatment. All patients will be followed when on study treatment
and after completion of study treatment during follow up period until death or the study
cutoff date, whichever comes first.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006504
  •   2015/01/09
  •   2011/03/03
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1117-8356 
  •   2010-022064-12 
  •   NCT01308567  (ClinicalTrials.gov)
  •   EFC11784  (Sanofi)
  •   2010-022064-12 
  •   U1111-1117-8356 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Prostate Cancer
  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Cabazitaxel (XRP6258)
  •   Drug: Docetaxel (XRP6976)
  •   Drug: Prednisone
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- overall survival; time frame: up to 57 months

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Progression Free Survival (PFS); time frame: up to 57 months

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Australia
  •   Belarus
  •   Brazil
  •   Canada
  •   China
  •   Czech Republic
  •   Denmark
  •   Finland
  •   France
  •   Germany
  •   Israel
  •   Italy
  •   Japan
  •   Mexico
  •   Peru
  •   Poland
  •   Portugal
  •   Romania
  •   Russian Federation
  •   Spain
  •   Sweden
  •   Taiwan, Province of China
  •   Turkey
  •   Ukraine
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2011/05/31
  •   1170
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion criteria :

- I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.

- I 02. Metastatic disease.

- I 03. Progressive disease while receiving hormonal therapy or after surgical
castration .

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion criteria:

- E 01. Prior chemotherapy for prostate cancer,

- E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy
or surgery to the time of randomization. Patients may be on biphosphonates prior to
study entry.

- E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of
bone marrow.

- E 04. Adverse events (excluding alopecia and those listed in the specific exclusion
criteria) from any prior anticancer therapy of grade >1(National Cancer Institute
Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.

- E 05. Less than 18 years (or country's legal age of majority if the legal age is >18
years).

- E 06. Eastern Cooperative Oncology Group (ECOG) performance status >2.

- E 07. History of brain metastases, uncontrolled spinal cord compression, or
carcinomatous meningitis or new evidence of brain or leptomeningeal disease.

- E 08. Prior malignancy.

- E 09. Participation in another clinical trial and any concurrent treatment with any
investigational drug within 30 days prior to randomization.

- E 10. Any of the following within 6 months prior to study enrollment: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.

- E 11. Any of the following within 3 months prior to randomization: treatment
resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or
inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled
thromboembolic event.

- E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV
disease requiring antiretroviral treatment.

- E 13. Any severe acute or chronic medical condition which could impair the ability of
the patient to participate to the study or interfere with interpretation of study
results, or patient unable to comply with the study procedures.

- E 14. Absence of signed and dated Institutional Review Board (IRB)-approved patient
informed consent form prior to enrollment into the study.

- E 15. Patients with reproductive potential who do not agree to use accepted and
effective method of contraception during the study treatment period.

- E 16. History of hypersensitivity to docetaxel, or polysorbate 80.

- E 17. Inadequate organ and bone marrow function

- E 18. Contraindications to the use of corticosteroid treatment.

- E 19. Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common
Terminology Criteria [NCI CTCAE] v.4.03).

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Sanofi
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Sanofi
    • Clinical Sciences & Operations 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Sanofi
    • Clinical Sciences & Operations 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
start of 1:n-Block dynamic attributes

Additional Trial Attributes

  • Urological disease 
  • If other, please specify 
  • Study recommendations 
  • If other, please specify 
  • German director of clinical investigation 
    start of 1:1-Block address
    • [---]*
    end of 1:1-Block address
    start of 1:1-Block address contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact
  • Further contact 
    start of 1:1-Block address
    • [---]*
    end of 1:1-Block address
    start of 1:1-Block address contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact
  • Function of contact 
  • Non-interventional study 
  • Stage 
  • If other, please specify 
  • Onset of therapy 
  • If other, please specify 
end of 1:n-Block dynamic attributes
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   3
  •   2016/01/14
* This entry means the parameter is not applicable or has not been set.